Email this article Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study
- Authors: Motzer R.1, Porta C.2,3, Alekseev B.4, Rha S.Y.5, Choueiri T.K.6, Mendez-Vidal M.J.7, Hong S.H.8, Kapoor A.9, Goh J.C.10, Eto M.11, Bennett L.12, Wang J.12, Pan J.J.13, Saretsky T.L.14, Perini R.F.14, He C.S.13, Mody K.13, Cella D.15
-
Affiliations:
- Memorial Sloan Kettering Cancer Center
- Interdisciplinary Department of Medicine, University of Bari A Moro
- University of Pavia
- P.A. Herzen Moscow Oncological Research Institute
- Yonsei Cancer Center, Yonsei University Health System
- Dana-Farber Cancer Institute
- Maimonides Institute for Biomedical Research of Cordoba Hospital, Universitario Reina Sofía
- Seoul St Mary’s Hospital, The Catholic University of Korea
- McMaster University
- ICON Research, South Brisbane and Queensland University of Technology
- Kyushu University
- RTI Health Solutions, Research Triangle Park
- Eisai
- Merck & Co
- Northwestern University
- Issue: Vol 18, No 2 (2022)
- Pages: 39-57
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCER
- Published: 12.08.2022
- URL: https://oncourology.abvpress.ru/oncur/article/view/1607
- DOI: https://doi.org/10.17650/1726-9776-2022-18-2-39-57
- ID: 1607
Cite item
Full Text
Abstract
.
About the authors
R. Motzer
Memorial Sloan Kettering Cancer Center
Author for correspondence.
Email: motzerr@mskcc.org
Robert Motzer
Department of Medicine
United StatesC. Porta
Interdisciplinary Department of Medicine, University of Bari A Moro; University of Pavia
Department of Biomedical Sciences and Human Oncology, University of Pavia
ItalyB. Alekseev
P.A. Herzen Moscow Oncological Research Institute
Department of Oncourology
Russian FederationS. Y. Rha
Yonsei Cancer Center, Yonsei University Health System
Сеул
Korea, Republic ofT. K. Choueiri
Dana-Farber Cancer Institute
Department of Medical Oncology
United StatesM. J. Mendez-Vidal
Maimonides Institute for Biomedical Research of Cordoba Hospital, Universitario Reina Sofía
Кордова
SpainS. H. Hong
Seoul St Mary’s Hospital, The Catholic University of Korea
Сеул
Korea, Republic ofA. Kapoor
McMaster University
Гамильтон, Онтарио
CanadaJ. C. Goh
ICON Research, South Brisbane and Queensland University of Technology
Брисбен, Квинсленд
AustraliaM. Eto
Kyushu University
Фукуока
JapanL. Bennett
RTI Health Solutions, Research Triangle Park
Штат Северная Каролина
United StatesJ. Wang
RTI Health Solutions, Research Triangle Park
Штат Северная Каролина
United StatesJ. J. Pan
Eisai
Натли, штат Нью-Джерси
United StatesT. L. Saretsky
Merck & Co
Кенилворт, штат Нью-Джерси
United StatesR. F. Perini
Merck & Co
Кенилворт, штат Нью-Джерси
United StatesC. S. He
Eisai
Натли, штат Нью-Джерси
United StatesK. Mody
Eisai
Натли, штат Нью-Джерси
United StatesD. Cella
Northwestern University
Department of Medical Social Sciences
United StatesReferences
Supplementary files
